1. Scrip
  3. >>Clinical Trials

Arcus’s CD73 Inhibitor Could Turn ‘Cold’ Pancreatic Cancer ‘Hot’

 
• By Andrew McConaghie

There are promising early signals from the novel mechanism, but Arcus’ fortunes remain tied to results from the TIGIT field.

Arcus Biosciences

Arcus Biosciences is best known for its efforts to develop a TIGIT immunotherapy with Gilead, but the partners are also working on quemliclustat, a CD73 inhibitor, which has just produced promising Phase I data.

High CD73 expression is associated with significantly poorer prognosis in several tumor types, but the new data raise hopes that quemliclustat could turn these ‘cold’ tumors ‘hot’,

Key Takeaways

  • Arcus is known for its TIGIT collaboration with Gilead, but has other oncology modalities in its pipeline

  • These include CD73 inhibitor quemliclustat, which could make ‘cold’ tumors responsive to chemotherapy and immunotherapy

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.